9th Oct 2007 14:42
Skyepharma PLC09 October 2007 FOR IMMEDIATE RELEASE 9 October 2007 SkyePharma PLC APPOINTMENT OF NON-EXECUTIVE CHAIRMAN LONDON, UK - 9 October 2007 -- SkyePharma PLC (LSE: SKP) today announces thatJeremy Scudamore has been appointed as the new Non-Executive Chairman of theCompany with effect from 15 October 2007 replacing Dr Jerry Karabelas, thecurrent Non-Executive Chairman. He will also be appointed as a member of theNomination & Governance Committee. Dr Karabelas, who was appointed as Non-Executive Chairman in February 2006, willstay on as a Non-Executive Director of the Company. Mr Scudamore, 60, has over 35 years' experience in the life sciences industry.From 1971 he worked for ICI and later Zeneca in a number of senior roles. In1999 he led the £1.3 bn buyout of Zeneca Specialities from AstraZeneca, thelargest private equity buyout in Europe to that date, becoming Chief Executiveand subsequently Chairman of the newly formed Avecia Group. Mr Scudamore is currently the Senior Non-Executive Director of ARM Holdings plcand is Chairman of Oxford Advanced Surfaces Ltd, the BoardLink Group Ltd and theNorth West Science Council. He is also a Non-Executive Director of Stem CellSciences plc and Oxford Catalysts Group plc. Dr Jerry Karabelas, Non-Executive Chairman of SkyePharma PLC said: "We aredelighted that Jeremy is joining SkyePharma as Non-Executive Chairman at suchan exciting time for the Company. He brings with him a wealth of knowledge andexperience of large and small companies in the life science and technologysectors." Jeremy Scudamore said "I am very pleased to join SkyePharma as Non-ExecutiveChairman and look forward to working closely with the other members of the Boardas the Company's lead product, FlutiformTM, advances through the final stages ofits development programme." Disclosures Required under Listing Rules 9.6.13 Current directorships are noted above. His previous directorships at publiclylisted companies over the past five years were at Avecia Group plc and CyprotexPLC. There are no further disclosures required under section 9.6.13 of theListing Rules. For further information please contact: SkyePharma PLC Frank Condella, Chief Executive Officer Ken Cunningham, Chief Operating Officer +44 207 491 1777 Peter Grant, Finance Director Financial Dynamics (London enquiries) David Yates / Deborah Scott +44 207 831 3113 Trout Group (US enquiries) Christine Labaree / Seth Lewis +1 617 583 1308 About SkyePharma PLC Using its proprietary drug delivery technologies, SkyePharma develops newformulations of known molecules to provide a clinical advantage and life-cycleextension. The Company has eleven approved products in the areas of oral,inhalation and topical delivery. The Group's products are marketed throughoutthe world by leading pharmaceutical companies. For more information, visitwww.skyepharma.com. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
SKP.L